Urate Lowering Therapy with Febuxostat in Daily Practice—A Multicentre, Open-Label, Prospective Observational Study

Introduction. Febuxostat, a novel xanthine oxidase inhibitor for the treatment of symptomatic hyperuricemia, showed superiority over allopurinol in the reduction of serum uric acid levels in pivotal studies. Whether this holds true the FORTE (febuxostat in the oral urate lowering treatment: effectiv...

Descripción completa

Detalles Bibliográficos
Autores principales: Tausche, Anne-Kathrin, Reuss-Borst, Monika, Koch, Ute
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2014
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4167949/
https://www.ncbi.nlm.nih.gov/pubmed/25276138
http://dx.doi.org/10.1155/2014/123105

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4167949/
https://www.ncbi.nlm.nih.gov/pubmed/25276138
http://dx.doi.org/10.1155/2014/123105

Ejemplares similares